Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Henrik Klitgaard"'
Autor:
Clara Mayer, Lluís Riera-Ponsati, Sakari Kauppinen, Henrik Klitgaard, Janine T. Erler, Stine N. Hansen
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Neurodegenerative diseases constitute a global health issue and a major economic burden. They significantly impair both cognitive and motor functions, and their prevalence is expected to rise due to ageing societies and continuous population growth.
Externí odkaz:
https://doaj.org/article/ed186951ce8645ee905a86c980cc5ef6
Publikováno v:
RNA Biology, Vol 19, Iss 1, Pp 594-608 (2022)
RNA therapeutics comprise a diverse group of oligonucleotide-based drugs such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs) that can be designed to selectively interact with drug targets curren
Externí odkaz:
https://doaj.org/article/59b6bf0a675a472594fab016df0d96f8
Autor:
Mika Naganawa, Jean-Dominique Gallezot, Sjoerd J. Finnema, Ralph Paul Maguire, Joël Mercier, Nabeel B. Nabulsi, Sophie Kervyn, Shannan Henry, Jean-Marie Nicolas, Yiyun Huang, Ming-Kai Chen, Jonas Hannestad, Henrik Klitgaard, Armel Stockis, Richard E. Carson
Publikováno v:
EJNMMI Research, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Background Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor. BRV showed faster entry into the hu
Externí odkaz:
https://doaj.org/article/22d2f1f3be124f3691b641c2f77893e1
Autor:
Wassilios Meissner, Paula Ravenscroft, René Reese, Daniel Harnack, Rudolf Morgenstern, Andreas Kupsch, Henrik Klitgaard, Bernard Bioulac, Christian E. Gross, Erwan Bezard, Thomas Boraud
Publikováno v:
Neurobiology of Disease, Vol 22, Iss 3, Pp 586-598 (2006)
Since electrophysiological correlates of l-dopa-induced dyskinesia (LID) are almost unknown, changes of striatal dopamine (DA) transmission and electrophysiological activity of the substantia nigra pars reticulata (SNr) were recorded before and after
Externí odkaz:
https://doaj.org/article/4da3bb6f59824e8298804c1f9f222a63
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 372:11-20
The antiepileptic drug (AED) candidate, (4R)-4-(2-chloro-2,2-difluoroethyl)-1-{[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl}pyrrolidin-2-one (padsevonil), is the first in a novel class of drugs that bind to synapt
Autor:
Jean-Marie Nicolas, Jonas Hannestad, Steven DeBruyn, Samantha Rossano, Yiyun Huang, Sjoerd J. Finnema, Mika Naganawa, Rafal M. Kaminski, Nabeel Nabulsi, Pierandrea Muglia, Christian Otoul, Hong Gao, Paul Martin, Joël Mercier, Henrik Klitgaard, Richard E. Carson, Armel Stockis, Shannan Henry, Richard Pracitto, David Matuskey, Sophie Kervyn, Ralph Paul Maguire
Publikováno v:
Epilepsia
Summary Objective Brivaracetam (BRV) and levetiracetam (LEV) are antiepileptic drugs that bind synaptic vesicle glycoprotein 2A (SV2A). In vitro and in vivo animal studies suggest faster brain penetration and SV2A occupancy (SO) after dosing with BRV
Autor:
Manuel Toledo, John M. Stern, Joseph I Sirven, Patricia A. Zipfel, Kristen Ricchetti-Masterson, Pavel Klein, Brien J. Smith, Brian D. Moseley, Henrik Klitgaard, Bernhard J. Steinhoff, Cédric Laloyaux, Vicente Villanueva, Felix Rosenow
Publikováno v:
Epilepsybehavior : EB. 118
Purpose To understand the currently available post-marketing real-world evidence of the incidences of and discontinuations due to the BAEs of irritability, anger, and aggression in people with epilepsy (PWE) treated with the anti-seizure medications
Autor:
Michael Wong, Mustafa Q. Hameed, Alexander Rotenberg, Guy Bar-Klein, Wolfgang Löscher, Alon Friedman, Twyman Roy E, Annamaria Vezzani, Henrik Klitgaard, Mathias Koepp, David A. Prince, Pavel Klein, Rafal M. Kaminski, Sergiusz Jozwiak
Publikováno v:
Epilepsia
Prevention of epilepsy is a great unmet need. Acute central nervous system (CNS) insults such as traumatic brain injury (TBI), cerebrovascular accidents (CVA), and CNS infections account for 15%-20% of all epilepsy. Following TBI and CVA, there is a
Autor:
Jean-Michel Rigo, Isabelle Niespodziany, Gustave Moonen, Henrik Klitgaard, Alain Matagne, Christian Wolff
Publikováno v:
Epilepsia. 58:e157-e161
Brivaracetam (BRV) is a selective, high-affinity ligand for synaptic vesicle protein 2A (SV2A), recently approved as adjunctive treatment for drug-refractory partial-onset seizures in adults. BRV binds SV2A with higher affinity than levetiracetam (LE
Autor:
Claude G. Wasterlain, Kerry Thompson, Alain Matagne, Lucie Suchomelova, Jerome Niquet, Henrik Klitgaard
Publikováno v:
Epilepsia, vol 58, iss 7
SummaryObjective To evaluate acute and long-term effects of intravenous brivaracetam (BRV) and BRV + diazepam (DZP) combination treatment in a rat model of self-sustaining status epilepticus (SSSE). Methods Rats were treated with BRV (10 mg/kg) 10 mi